Platinum(IV) oxide

Base Information

• Chemical Name: Platinum(IV) oxide
• CAS No.: 1314-15-4
• Molecular Formula: PtO2
• Molecular Weight: 227.079
• Hs Code.: 28439000
• European Community (EC) Number: 215-223-0
• NSC Number: 402624
• DSSTox Substance ID: DTXSID40904275
• Wikipedia: Adams%27_catalyst,Adams'_catalyst
• Wikidata: Q1851782
• Mol file: 1314-15-4.mol

Synonyms:platinum oxide;PtO2

Chemical Property of Platinum(IV) oxide

Chemical Property:

• Appearance/Colour: crystalline
• Melting Point: 450 °C(lit.)
• PSA: 34.14000
• Density: 10.2
• LogP: -0.24010
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility.: THF, o-xylene, chloroform, chlorobenzene and dichlorobenzene
• Water Solubility.: Soluble in caustic potash solution. Insoluble in water, acid, aquaregia.
• Hydrogen Bond Donor Count: 0
• Hydrogen Bond Acceptor Count: 2
• Rotatable Bond Count: 0
• Exact Mass: 226.954624
• Heavy Atom Count: 3
• Complexity: 18.3

Purity/Quality:

99% ^*data from raw suppliers

Platinum(IV) oxide ^*data from reagent suppliers

Safty Information:

• Pictogram(s): O,Xi
• Hazard Codes: O,Xi
• Statements: 8-36-41-38-36/37/38
• Safety Statements: 26-36/37/39-28A-22-17-36

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Chemical Classes: Metals -> Metals, Inorganic Compounds
• Canonical SMILES: O=[Pt]=O
• Uses: ▼▲ Industry Application Role/benefit Hydrogenation Reduction of alkynes to alkenes Catalyst/ In the presence of H2，PtO2 can be reduced to Pt black which is the active form Hydrogenation of nitro compounds to amines Hydrogenation of ketones The removal of phenyl groups attached to a heteroatom Reduction of aromatic ring Dehydrogenation Dehydrogenation of 1,4-diketone to pyridazine Oxidation Oxidation of alcohols to carbonyl compounds Others Resistance Low resistance range Hydrogen absorbing material Excellent hydrogen absorbing capacity Thick film circuit and electronic component Insoluble in aqueous solutions (water) and extremely stable Solid oxide fuel cells and oxygen generation systems Cathode/certain perovskite structured oxides are electronically conductive As catalyst in hydrogenations. The actual catalyst is platinum black which is formed in situ by reduction of the PtO2 by the hydrogen used for the hydrogenation. Especially useful for reduction at room tempereture and hydrogen pressures up to 4 atmospheres. Suitable for the reduction of double and triple bonds, aromatic nuclei, carbonyl groups, nitro groups, and nitriles. Platinum(IV) oxide is used as catalyst for hydrogenation reactions. It is applied in the hydrogenation of alkenes to alkanes, nitro compounds to amines and ketones to alcohols. It is also involved in the hydrogenolysis of cyclopropyl group in to an isopropyl group and in selective oxidation of primary alcohols. Platinum(IV) oxide has been used for the reduction of citernyl bromide to form (S)-3,7-dimethyloctylbromide.
• Description: PTO2 is an alternating wide band-gap copolymer?with electron-donating benzodithiophene (BDT) and? electron-withdrawing?thiophene carboxylate ester as the main backbone units. PTO2 enjoys good solubility in non-halogenated solvents, i.e. xylenes and THF.

Technology Process of Platinum(IV) oxide

There total 22 articles about Platinum(IV) oxide which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield:

silver platinum(IV) rhodanide → platinum(IV) oxide (1314-15-4) + potassium thioacyanate (333-20-0) + silver (I) oxide (155645-84-4,20667-12-3)

Guidance literature:

With potassium hydroxide; In not given;

Reference yield:

oxygen (80937-33-3) + platinum (7440-06-4) → platinum(IV) oxide (1314-15-4)

Guidance literature:

In neat (no solvent); at 10E-1-10E5 Pa at high temp. (1300-1600°C); Kinetics;

DOI:10.1016/0022-5088(81)90141-7

Reference yield:

water (7732-18-5) + platinum(IV) chloride (13454-96-1) → platinum(IV) oxide (1314-15-4)

Guidance literature:

With base (NaOH); In water; 4 equiv. of C12H25(CH3)2N(1+)(CH2)3COO(1-) betain stabilizer, 50°C, 7 days; UV-vis spectroscopy;

DOI:10.1021/ja9906498

upstream raw materials:

oxygen

platinum

water

platinum(IV) chloride

Downstream raw materials:

4-Bromo-2-[2-[3-bromophenyl]ethyl]benzoic acid

thioorthocarbonotrifluoridic acid 4-amino-phenyl ester

methyl 2-p-(2-[(2-hydroxy-3-phenoxypropyl)amino]propoxy)-phenoxyacetate

4-n-Propoxy-3-chloro-phenylacetyl-glycine methyl ester

Refernces

Synthesis of lipid A type carboxymethyl derivatives with ether chains instead of ester chains and their LPS-antagonistic activities

10.1016/S0008-6215(02)00357-9

The research aimed to synthesize lipid A type carboxymethyl derivatives with ether chains instead of ester chains and evaluate their LPS-antagonistic activities. The purpose was to investigate the potential of these compounds as immunosuppressants and in the treatment of autoimmune diseases and septicemia by deactivating LPS-induced aggressive macrophages. The study focused on the synthesis and biological activities of compounds 18, 19, and 20, which were designed to have ether chains at the C-3 and C-3' positions. The synthesis involved a series of chemical reactions using reagents such as NaH, DMF, NaOH, DCC, DMAP, OsO4, NMO, Pb(OAc)4, NaClO2, Ph2CN2, and PtO2, among others. The compounds were tested for their ability to inhibit LPS-induced TNFα production in human U937 cells, showing IC50 values of 6.5, 6.1, and 12.4 nM, respectively. The results indicated that the presence of an ester bond in the side chain at the 3-position might play a significant role in the LPS-antagonistic activity, as the ether chain compounds showed less activity compared to a related compound with an ester side chain (IC50=0.6 nM). The study concluded that the synthesized compounds exhibited LPS-antagonistic activity, albeit with varying potencies, and could serve as potential candidates for further development in immunomodulation therapies.